Literature DB >> 6760338

Urinary tract infections due to Candida albicans.

J F Fisher, W H Chew, S Shadomy, R J Duma, C G Mayhall, W C House.   

Abstract

Infection of the urinary tract due to Candida albicans is an uncommon but well-described complication of modern therapeutics. Despite the rarity of this infection, culture of properly collected urine yielding C. albicans requires an explanation. The significance of systemic factors in the defense of the urinary tract against candidal infection is unknown, but secretions from the prostate gland in men and from periurethral glands in women have been reported to be fungistatic. In addition, growth of Candida at sites on mucous membranes may be suppressed by other normal flora. Conditions that predispose to candiduria include diabetes mellitus, antibiotic and corticosteroid therapy, as well as factors such as local physiology and disturbance of urine flow. Lower urinary tract candidiasis is usually the result of a retrograde infection, while renal parenchymal infection most often follows candidemia. In addition to asymptomatic candiduria, recognized clinical forms of candidal urinary tract infections include bladder infection, renal parenchymal infection, and infections associated with fungus ball formation. Unfortunately, clinical criteria alone are insufficient to distinguish reliably among these clinical types. If the urine is found to contain candidal organisms, the condition of the patient should be considered for determination of appropriate therapy. When infection is thought to be confined to the bladder, patients without indwelling bladder catheters should be considered for flucytosine therapy. For patients requiring indwelling bladder catheterization, irrigation with amphotericin B is usually successful. Although flucytosine alone may be useful for renal parenchymal candidal infection, iv amphotericin B alone or the combination of amphotericin B and flucytosine is indicated when systemic candidiasis cannot be excluded.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6760338     DOI: 10.1093/clinids/4.6.1107

Source DB:  PubMed          Journal:  Rev Infect Dis        ISSN: 0162-0886


  20 in total

1.  Candiduria: When and How to Treat It.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  2000-12       Impact factor: 3.725

2.  Clearance of Candida colonizing the urinary bladder by a two-day amphotericin B irrigation.

Authors:  C C Hsu; B Ukleja
Journal:  Infection       Date:  1990 Sep-Oct       Impact factor: 3.553

3.  Treatment of an infant with Candida cystitis.

Authors:  S B Conley; M O'Ryan; E S Buescher; R J Portman; J M Lemire; J N Corriere
Journal:  Pediatr Nephrol       Date:  1991-03       Impact factor: 3.714

Review 4.  Antifungal agents: chemotherapeutic targets and immunologic strategies.

Authors:  N H Georgopapadakou; T J Walsh
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

5.  Surface-active properties of Candida albicans.

Authors:  S A Klotz
Journal:  Appl Environ Microbiol       Date:  1989-09       Impact factor: 4.792

6.  Fluconazole (UK-49,858) treatment of candidiasis in normal and diabetic rats.

Authors:  M A Fisher; P G Lee; W F Tarry
Journal:  Antimicrob Agents Chemother       Date:  1989-07       Impact factor: 5.191

Review 7.  Fungal urinary tract infections in the elderly: treatment guidelines.

Authors:  L G Jacobs
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

8.  Fungicidal effect of amphotericin B in urine: in vitro study to assess feasibility of bladder washout for localization of site of candiduria.

Authors:  I W Fong; P C Cheng; N A Hinton
Journal:  Antimicrob Agents Chemother       Date:  1991-09       Impact factor: 5.191

9.  Anuria in a premature infant due to ureteropelvic fungal bezoars.

Authors:  J Laufer; B Reichman; M Graif; M Brish
Journal:  Eur J Pediatr       Date:  1986-04       Impact factor: 3.183

10.  Candiduria in critically ill patients admitted to intensive care medical units.

Authors:  Francisco Alvarez-Lerma; Juan Nolla-Salas; Cristobal León; Mercedes Palomar; Ricard Jordá; Nieves Carrasco; Felipe Bobillo
Journal:  Intensive Care Med       Date:  2003-05-16       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.